Genetic Study of Schizophrenia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

4914 participants

Study Classification

OBSERVATIONAL

Study Start Date

1995-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This large ongoing study at NIMH investigates the neurobiology of schizophrenia by identifying susceptibility genes, evaluating their impact on brain function to better understand how to treat and prevent this illness....

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Genetic Basis of Inherited Neurologic Deficits in People With Schizophrenia

NCT00247637

Schizophrenia

COMPLETED

A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations

NCT01075373

Schizophrenia

UNKNOWN

Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors

NCT00178932

Schizophrenia Schizoaffective Disorder Bipolar Disorder +1 more

COMPLETED NA

Neurophysiological Studies in Schizophrenia and Psychiatric Disorders

NCT01384604

Schizophrenia Schizoaffective Disorder Bipolar Disorder

COMPLETED

Genetics of Schizophrenia

NCT00619437

Schizophrenia

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objective: Schizophrenia is a complex genetic disorder which likely involves many genes each producing a slight increase in risk. Finding weak-acting genes in complex genetic disorders has been challenging and will likely require a number of approaches and large clinical samples. Several strategies have emerged recently that appear to markedly improve the power of genetic studies for detecting such genes. These include using association (rather than linkage) and using intermediate phenotypes in addition to DMS-IV diagnosis.

Study Population: We propose to take advantage of these techniques by studying quantitative traits related to schizophrenia in patients, siblings, and controls.

Design: We will employ an association design, rather than linkage. Traits will include quantifiable neurobiological variables that have been implicated previously as possible phenotypes related to schizophrenia. These include tests of attention and cognition.

Outcome Measure: We will use several statistical methods to show that specific genetic polymorphisms affect these phenotypes, including case control and family based association studies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizoaffective Disorder Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal Controls

Male and female adult healthy volunteers

No interventions assigned to this group

Parents

Parents of Probands and siblings for the purposes of DNA collection

No interventions assigned to this group

Probands

Adult Subjects with Schizophrenia Spectrum Disorders

No interventions assigned to this group

Siblings

Adult siblings of Probands

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Probands must have a DSM IV-R diagnosis of schizophrenia,schizoaffective disorder, psychosis N.O.S. or schizophreniform disorder.
* Probands and Siblings must be between the ages of 18 and 55
* Probands and Siblings must be free of major medical illnesses, but may have controlled hypertension, thyroid disease, or diabetes.
* Probands and Siblings must have the cognitive ability to consent for themselves. Those who are judged to have the cognitive ability to consent for themselves at the time of participation, but do not have the legal capacity to consent for themselves may participate if the legal guardian /Legal authorized representative (LAR) provides consent by signing the informed consent form.
* Fluency in English is required.

To be eligible for this research study, healthy volunteers must be:

* Between the ages of 18 and 55
* Fluency in English is required

Exclusion Criteria

* Seizure disorder, mental retardation, organic brain damage or other neurological disease.
* History of any (excepting nicotine-related) DSM5-defined moderate to severe substance use disorder (or DSM-IV-defined substance dependence).
* Cumulative lifetime history of any (excepting nicotine-related) DSM5-defined mild substance use disorder (or any DSM-IV-defined substance abuse), either in excess of 5 years total or not in remission for at least 6 months.
* Head trauma with loss of consciousness over 5 minutes from all but genetic sampling.
* Chemotherapy.
* NIMH employees/staff and their immediate family members will be excluded from the study per NIMH policy

Siblings who do not qualify for the 2-day or 1-day study, may participate in the limited phenotyping arm in which only a psychiatric interview and a blood draw for genetic analysis (SCID-DNA) will be performed, case control analysis or be included as part of a trio (one parent, one sibling, one patient) to study genetic transmission from parents to offsprings.. All parents are eligible for the study.

They will not be eligible if:

* They have history of DSM IV-R psychiatric diagnosis or severe chronic medical illness at the time of the study.
* They have a history of any (excepting nicotine-related) DSM5-defined moderate to severe substance use disorder (or DSM-IV-defined substance dependence).
* They have a cumulative lifetime history of any (excepting nicotine-related) DSM5-defined mild substance use disorder (or any DSM-IV-defined substance abuse), either in excess of 5 years total or not in remission for at least 6 months.
* They may not be eligible for the 2-day or 1-day study if they have a first-degree relative with history of schizophrenia spectrum disorders. However, they may be included in the SCID\_DNA or case control analyses.
* Healthy volunteers must be free of learning disabilities.
* NIMH employees/staff and their immediate family members will be excluded from the study per NIMH policy.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No